Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVEc vaccine for ricin poisoning prevention
NCT02385825Phase 1Withdrawn
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Apr 2016
- Primary completion
- Jun 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ricin vaccine RVEc in Ricin poisoning (3 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Percentage of vaccinated subjects without adverse events at Day 730, Percentage of vaccinated subjects with any severity of local reactions at Day 730 and 1 more. Planned start Apr 2016; status: withdrawn.
02
Drugs
ricin vaccine RVEc
03
Conditions
Ricin poisoning
Beyond the preview
Go deeper on NCT02385825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385825.